Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis
- 31 May 2005
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 4 (2), 101-105
- https://doi.org/10.1016/j.jcf.2004.11.004
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPDChest, 2003
- Ventilation-Perfusion Response After Fenoterol in Hypoxemic Patients With Stable COPDChest, 1996
- Is an Anticholinergic Agent Superior to a β2-Agonist in Improving Dyspnea and Exercise Limitation in COPD?Chest, 1995
- Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosisRespiratory Medicine, 1994
- Endurance exercise capacity in adults with cystic fibrosisRespiratory Medicine, 1993
- Increased physiological dead space during exercise after bronchodilation in cystic fibrosis.Pediatric Pulmonology, 1993
- Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.Thorax, 1989
- Salbutamol and ipratropium in partially reversible airway obstructionRespiratory Medicine, 1987
- Dose-response study of inhaled salbutamol powder in chronic airflow obstruction.Thorax, 1983
- Exercise Conditioning and Cardiopulmonary Fitness in Cystic FibrosisChest, 1981